TD Cowen analyst Mark Frahm reiterated a Buy rating on Kymera Therapeutics (NASDAQ: KYMR).The analyst commented, "KYMR disclosed that after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE